Epigenomics AG
ISIN: DE000A3H2184 | Ticker: ECX | LEI: 549300X1C4U862NDLN97
Country: Germany
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as colorectal, liver, and lung cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.
Year founded1998
Served areaWorldwide
Headcount32
HeadquartersGeneststraße 5, 10829 Berlin – Germany
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 27.12.22 | Ho, Dr. Selwyn | Board | Buy | EUR 4,200.00 |
| 23.12.22 | von Prondzynski, Heino | Supervisory board | Buy | EUR 5,625.00 |
| 22.12.22 | Ahlers, Felix | Board | Other | EUR 22,000.00 |
| 22.12.22 | Lubenow, Dr. Helge | Supervisory board | Buy | EUR 1,934.20 |
| 20.12.22 | von Prondzynski, Heino | Supervisory board | Buy | EUR 3,680.00 |
| 16.12.22 | Lindenice GmbH | Board | Buy | EUR 7,400.00 |
| 16.12.22 | Ho, Dr. Selwyn | Board | Buy | EUR 6,780.00 |
| 14.12.22 | von Prondzynski, Heino | Supervisory board | Buy | EUR 40,000.00 |
DE000A3H2184
LEI549300X1C4U862NDLN97
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryPareto Securities
Listed Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.